AFM13, an NKCE targeting CD30 on tumor cells and CD16a on NK cells, has demonstrated promising results in clinical trials for Hodgkin lymphoma and CD30-positive solid tumors [62,63]. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.